Physician profile
Michael Soler
NPI 1285901140
$4,987.10
in general payments reported to CMS, 2019-2025
35 companies · $618 in 2025
The $618 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,888 · 2020: $1,884 · 2023: $32.87 · 2024: $565 · 2025: $618.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,196 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,196.37 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $568.89 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $566.01 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $447.82 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $382.75 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $293.88 | 2019-2024 | Xarelto |
| Amgen INC. | $267.72 | 2019-2024 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $267.54 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Sanofi-Aventis U.S. LLC | $240.38 | 2019-2020 | |
| Allergan, INC. | $237.31 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $198.76 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $182.50 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $166.42 | 2019-2024 | Xifaxan |
| Abbvie INC. | $132.81 | 2019-2025 | |
| Mylan Specialty L.P. | $122.71 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $94.35 | 2023-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $85.01 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $77.81 | 2024-2025 | Gemtesa |
| Abbott Laboratories | $60.76 | 2019-2025 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $60.22 | 2024-2025 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $57.99 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $55.83 | 2019-2020 | |
| Ardelyx, INC. | $54.31 | 2025 | Ibsrela |
| Eisai INC. | $51.85 | 2020 | |
| Shire North American Group INC | $46.11 | 2019 | |
| Radius Health, INC. | $42.52 | 2019-2020 | |
| Exact Sciences Corporation | $39.69 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Amarin Pharma, INC. | $39.51 | 2020 | |
| Genentech USA, INC. | $29.89 | 2019-2020 | |
| Astellas Pharma US INC | $28.11 | 2019-2020 | |
| Dexcom, INC. | $18.67 | 2025 | Dexcom G6 Transmitter |
| Arbor Pharmaceuticals, INC. | $15.28 | 2019 | |
| Lundbeck LLC | $14.65 | 2024 | Rexulti |
| Esperion Therapeutics, INC. | $14.34 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $13.80 | 2020 | |
| Philips North America LLC | $10.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Soler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.